Apremilast (trade name: Otezla) has been available since January 2015 for the treatment of moderate to severe plaque psoriasis or active psoriatic arthritis in adult patients in whom certain pretreatments are not sufficiently effective or unsuitable. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in two dossier assessments whether this drug offers an added benefit over the respective appropriate comparator therapy. Such an added benefit cannot be derived from any of the dossiers however, because they contain no relevant data.

For more details, go to: https://www.iqwig.de/en/press/press-releases/press-releases/apremilast-in-plaque-psoriasis-and-psoriatic-arthritis-no-added-benefit-can-be-derived.6708.html